Literature DB >> 9498756

Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines.

M C Gilfillan1, P J Noel, E R Podack, S L Reiner, C B Thompson.   

Abstract

Costimulation was originally defined and characterized during primary T cell activation. The signaling events that regulate subsequent antigen encounters by T cells are less well defined. In this study we examined the role of CD30 in T cell activation and defined factors that regulate expression of CD30 on T cells. We demonstrate that CD30 expression is restricted to activated T cells and regulated by CD28 signal transduction. In contrast to CD28-expressing TCR Tg cells, CD28-deficient TCR Tg cells did not express CD30 when cultured with peptide and APCs. However, rIL-4 reconstituted CD30 expression on CD28-deficient TCR Tg cells. Blockade of CD28 interactions or depletion of IL-4 inhibited the induction of CD30, suggesting that both CD28 and IL-4 play important roles in the induction of CD30 expression on wild-type cells. However, CD28 signaling did not up-regulate CD30 expression solely through its ability to augment IL-4 production because IL-4-deficient T cells stimulated with anti-CD3 and anti-CD28 expressed CD30. Induction of CD30 in the absence of IL-4 was not due to the IL-4-related cytokine IL-13. CD30, when expressed on an activated T cell, can act as a signal transducing receptor that enhances the proliferation of T cells responding to CD3 crosslinking. Collectively, the data suggest that T cell expression of CD30 is dependent on the presence of CD28 costimulatory signals or exogenous IL-4 during primary T cell activation. Once expressed on the cell surface, CD30 can serve as a positive regulator of mature T cell function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9498756

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Regulation of CD30 antigen expression and its potential significance for human disease.

Authors:  M E Kadin
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  The effect of IL-18 on IL-12-induced CD30 expression and IL-4 and IFN-gamma production by allergen and PPD specific T cells.

Authors:  M Tarkowski; S Chrul; J Bodalski
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

3.  Increased levels of soluble CD30 in plasma of patients with Plasmodium falciparum malaria.

Authors:  Kåre Kemp; Jørgen A L Kurtzhals; Bartholomew D Akanmori; Victoria Adabayeri; Bamenla Q Goka; Charlotte Behr; Lars Hviid
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

Review 4.  CD30+ Lymphoproliferative Disorders of the Skin.

Authors:  Maxwell B Sauder; John T O'Malley; Nicole R LeBoeuf
Journal:  Hematol Oncol Clin North Am       Date:  2017-04       Impact factor: 3.722

5.  Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells.

Authors:  A Cerutti; A Schaffer; R G Goodwin; S Shah; H Zan; S Ely; P Casali
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

6.  Lipopolysaccharide-dependent down-regulation of CD27 expression on T cells activated with superantigen.

Authors:  K Kai; H Rikiishi; S Sugawara; M Takahashi; H Takada; K Kumagai
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

Review 7.  TNF superfamily: costimulation and clinical applications.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Cell Biol Int       Date:  2009-02-20       Impact factor: 3.612

Review 8.  Function of tumor necrosis factor receptor family members on regulatory T-cells.

Authors:  Robert H Arch
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 9.  CD30: from basic research to cancer therapy.

Authors:  Hiromi Muta; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

10.  Proteomic analysis of serum in lung cancer induced by 3-methylcholanthrene.

Authors:  Minhua Li; Bo Ye; Yuxia Zhang; Honglei Chen; Dong Xia; Mingqiu Liu; Fei Yang
Journal:  J Biomed Biotechnol       Date:  2009-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.